Narrative Review: Fibrotic Diseases: Cellular and Molecular Mechanisms and Novel Therapies

@article{Rosenbloom2010NarrativeRF,
  title={Narrative Review: Fibrotic Diseases: Cellular and Molecular Mechanisms and Novel Therapies},
  author={J. Rosenbloom and S. V. Castro and S. Jimenez},
  journal={Annals of Internal Medicine},
  year={2010},
  volume={152},
  pages={159 - 166}
}
Abnormal and exaggerated deposition of extracellular matrix is the hallmark of many fibrotic diseases, including systemic sclerosis and pulmonary, liver, and kidney fibrosis. The spectrum of affected organs, the usually progressive nature of the fibrotic process, the large number of affected persons, and the absence of effective treatment pose an enormous challenge when treating fibrotic diseases. Delineation of the central role of transforming growth factor-beta (TGF-beta) and identification… Expand
Strategies for anti-fibrotic therapies.
TLDR
The origin of the myofibroblast is reviewed and the crucial regulatory pathways involving multiple growth factors and cytokines that participate in the pathogenesis of the fibrotic process are discussed. Expand
Human Fibrotic Diseases: Current Challenges in Fibrosis Research.
TLDR
Efforts to further clarify the complex pathogenetic mechanisms of the fibrotic process should be encouraged to attain the elusive goal of developing effective therapies for these serious, untreatable, and often fatal disorders. Expand
New frontiers in fibrotic disease therapies: The focus of the Joan and Joel Rosenbloom Center for Fibrotic Diseases at Thomas Jefferson University.
TLDR
This work examines the effectiveness of administration of several drug combinations in a mouse pneumoconiosis model and describes the potential utility of five non-invasive biomarkers found in urine and blood. Expand
Endothelial to Mesenchymal Transition (EndoMT) in the Pathogenesis of Human Fibrotic Diseases
TLDR
The evidence supporting EndoMT’s contribution to human fibrotic disease pathogenesis is reviewed, with a focus on the role of the phenotypic transition of endothelial cells into mesenchymal cells. Expand
Novel Anti-fibrotic Therapies
TLDR
The purpose of this review is to provide an overview of emerging antifibrotic agents that have shown encouraging results in preclinical or early clinical studies, but have not yet been approved for use in human disease. Expand
TGF-β-Induced Endothelial-Mesenchymal Transition in Fibrotic Diseases
TLDR
The role of the TGF-β signaling pathway and EndMT in the development of fibrotic diseases are summarized and their therapeutic potential is discussed. Expand
The significance of macrophage polarization subtypes for animal models of tissue fibrosis and human fibrotic diseases
TLDR
An overview of the current understanding of the role of monocyte/macrophage phenotype subpopulations in animal models of tissue fibrosis and in various systemic and organ-specific human fibrotic diseases is provided. Expand
Tyrosine Kinases in the Pathogenesis of Tissue Fibrosis in Systemic Sclerosis and Potential Therapeutic Role of their Inhibition.
TLDR
The role of receptor and non-receptor tyrosine kinases in the pathogenesis of the frequently progressive cutaneous and systemic fibrotic alterations in SSc, and the potential of TKIs as SSc disease-modifying antifibrotic therapeutic agents are reviewed. Expand
Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities
TLDR
Precise characterization of the deregulated extracellular and intracellular signaling pathways, mediators and cellular differentiation programs that contribute to fibrosis in SSc will facilitate the development of selective, targeted therapeutic strategies. Expand
Role of growth factors in the pathogenesis of tissue fibrosis in systemic sclerosis.
TLDR
The experimental evidence supporting the participation of various growth factors in the pathogenesis of the fibrotic process in SSc and the molecular mechanisms involved will be reviewed. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 135 REFERENCES
Molecular ablation of transforming growth factor beta signaling pathways by tyrosine kinase inhibition: the coming of a promising new era in the treatment of tissue fibrosis.
TLDR
It is the persistent activation of the genes encoding various collagens in these cells which distinguishes controlled repair, such as that occurring during normal wound healing, from the uncontrolled fibrosis which is the hallmark of the fibrotic diseases. Expand
Molecular pathways as novel therapeutic targets in systemic sclerosis
TLDR
The identification of novel signaling pathways and mediators that are altered in systemic sclerosis and contribute to tissue damage allows their selective targeting and opens the door for novel therapeutic strategies utilizing novel compounds, or innovative ways of using already-approved drugs. Expand
Mechanisms and consequences of fibrosis in systemic sclerosis
TLDR
Overall, this is an exciting time for new therapies in SSc and advances are being made in synchrony with an improved understanding of the molecular and biochemical basis of the disease. Expand
Molecular mechanisms of and possible treatment strategies for idiopathic pulmonary fibrosis.
TLDR
This review summarizes recent progress in understanding the molecular mechanisms of pulmonary fibrosis, and includes a more detailed discussion of the potential points of therapeutic attack in pulmonary fibrotic disease. Expand
Renal fibrosis: new insights into the pathogenesis and therapeutics.
TLDR
This mini-review attempts to highlight the recent progress in understanding of the cellular and molecular pathways leading to renal fibrosis, and discusses the challenges and opportunities in developing therapeutic strategies. Expand
Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis.
TLDR
The data indicate that fibroblasts respond to TGF-beta by stimulating c-Abl kinase activity independently of Smad2/3 phosphorylation or PDGFR activation, and that Abl family members represent common targets for the modulation of profibrotic cytokine signaling. Expand
Mechanisms of liver fibrosis.
TLDR
Many of the molecular events that occur following HSC activation and collagen gene regulation that contribute to the fibrogenic nature of these cells are described and a review of therapeutic strategies to treat this disease is provided. Expand
Pathobiology of transforming growth factor β in cancer, fibrosis and immunologic disease, and therapeutic considerations
TLDR
Several approaches are being studied to inhibit TGF-β activity, including neutralizing antibodies, soluble receptors, receptor kinase antagonist drugs, antisense reagents and a number of less specific drugs such as angiotensin II antagonists and tranilast. Expand
Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis.
TLDR
Clinical data from patients with chronic myelogenous leukaemia suggest that imatinib, nilotinib and dasatinib are well tolerated and trials with other tyrosine kinase inhibitors are in preparation for anti-fibrotic approaches. Expand
Effects of the Protein Kinase Inhibitor, Imatinib Mesylate, on Epithelial/Mesenchymal Phenotypes: Implications for Treatment of Fibrotic Diseases
TLDR
The capacity of a PKI to inhibit fibroblast proliferation may be insufficient to mediate significant antifibrotic effects in late stages of tissue injury repair, indicating that Pharmacologic agents that modulate the activities and fate of differentiated (myo)fibroblasts, without interfering with the regenerative capacity of epithelial cells, are likely to be more effective for treatment of nonresolving, progressive fibrotic disorders. Expand
...
1
2
3
4
5
...